[{"id":"1a19387e-f25a-41bd-b670-cc6fddc92951","acronym":"Nautilus","url":"https://clinicaltrials.gov/study/NCT05340621","created_at":"2022-04-22T14:53:50.824Z","updated_at":"2024-07-02T16:35:15.772Z","phase":"Phase 1/2","brief_title":"NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)","source_id_and_acronym":"NCT05340621 - Nautilus","lead_sponsor":"OnKure, Inc.","biomarkers":" BRAF • NRAS • KIT • NF1 • GNAQ","pipe":" | ","alterations":" NRAS mutation • RAS mutation","tags":["BRAF • NRAS • KIT • NF1 • GNAQ"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • bocodepsin (OKI-179)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 03/04/2026","primary_completion_date":" 03/04/2026","study_txt":" Completion: 04/04/2026","study_completion_date":" 04/04/2026","last_update_posted":"2024-03-07"}]